JP7772597B2 - 生物学的送達ビヒクルのための組成物及び方法 - Google Patents

生物学的送達ビヒクルのための組成物及び方法

Info

Publication number
JP7772597B2
JP7772597B2 JP2021573887A JP2021573887A JP7772597B2 JP 7772597 B2 JP7772597 B2 JP 7772597B2 JP 2021573887 A JP2021573887 A JP 2021573887A JP 2021573887 A JP2021573887 A JP 2021573887A JP 7772597 B2 JP7772597 B2 JP 7772597B2
Authority
JP
Japan
Prior art keywords
mol
lipid
delivery vehicle
glycero
dialkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021573887A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020252375A5 (https=
JP2022538797A (ja
JP2022538797A5 (https=
Inventor
アフマド、ムビージ
デイ、ティモシー
ハーフェズ、イスマイル
メリット、ジョン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Particella Inc
Original Assignee
Particella Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Particella Inc filed Critical Particella Inc
Publication of JP2022538797A publication Critical patent/JP2022538797A/ja
Publication of JPWO2020252375A5 publication Critical patent/JPWO2020252375A5/ja
Publication of JP2022538797A5 publication Critical patent/JP2022538797A5/ja
Application granted granted Critical
Publication of JP7772597B2 publication Critical patent/JP7772597B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A61K47/6909Micelles formed by phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5123Organic compounds, e.g. fats, sugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5176Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184Virus capsids or envelopes enclosing drugs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Optics & Photonics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Botany (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021573887A 2019-06-14 2020-06-12 生物学的送達ビヒクルのための組成物及び方法 Active JP7772597B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962861852P 2019-06-14 2019-06-14
US62/861,852 2019-06-14
US201962948095P 2019-12-13 2019-12-13
US62/948,095 2019-12-13
PCT/US2020/037579 WO2020252375A1 (en) 2019-06-14 2020-06-12 Compositions and methods for biological delivery vehicles

Publications (4)

Publication Number Publication Date
JP2022538797A JP2022538797A (ja) 2022-09-06
JPWO2020252375A5 JPWO2020252375A5 (https=) 2023-07-10
JP2022538797A5 JP2022538797A5 (https=) 2023-07-10
JP7772597B2 true JP7772597B2 (ja) 2025-11-18

Family

ID=73781318

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021573887A Active JP7772597B2 (ja) 2019-06-14 2020-06-12 生物学的送達ビヒクルのための組成物及び方法

Country Status (8)

Country Link
US (1) US20220296516A1 (https=)
EP (1) EP3982932A4 (https=)
JP (1) JP7772597B2 (https=)
CN (1) CN114286671A (https=)
AU (1) AU2020290516B2 (https=)
CA (1) CA3142949A1 (https=)
IL (1) IL288755A (https=)
WO (1) WO2020252375A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113166783B (zh) 2018-10-09 2024-10-11 不列颠哥伦比亚大学 包含无有机溶剂和去污剂的转染活性囊泡的组合物和系统以及与之相关的方法
US20230023615A1 (en) * 2019-12-13 2023-01-26 Dnalite Therapeutics, Inc. Compositions and methods for biological delivery vehicles
EP4259099A1 (en) * 2020-12-14 2023-10-18 Particella, Inc. Biological delivery systems
WO2022260678A1 (en) * 2021-06-11 2022-12-15 Dnalite Therapeutics, Inc. Compositions and methods for biological delivery vehicles
JPWO2022176953A1 (https=) * 2021-02-17 2022-08-25
WO2022211481A1 (ko) * 2021-04-01 2022-10-06 에스엔제이 파마 인크 생활성물질의 경구용 나노입자 및 이의 제조방법
KR102789632B1 (ko) * 2021-04-01 2025-04-01 에스엔제이 파마 인크 생활성물질의 경구용 나노입자 및 이의 제조방법
WO2023182812A1 (ko) * 2022-03-22 2023-09-28 주식회사 바이오엔 담즙산염 및 양이온성 펩타이드를 포함하는 단백질 전달용 조성물 및 이의 용도
CN117247359A (zh) * 2022-06-09 2023-12-19 中国科学院广州生物医药与健康研究院 一种树状样脂质化合物、脂质体、脂质复合物、脂质纳米颗粒及其应用
WO2024006863A1 (en) * 2022-06-30 2024-01-04 Precision NanoSystems ULC Lipid nanoparticle formulations for vaccines
CN118356505A (zh) * 2023-01-10 2024-07-19 复旦大学 含末端羟基的peg化纳米载体在制备规避人体预存抗peg抗体的药物制剂中的用途
AU2023457271A1 (en) * 2023-06-28 2025-12-18 Global Life Sciences Solutions Canada Ulc Lipid nanoparticle formulations for cell therapy and related methods
WO2025021286A1 (en) * 2023-07-23 2025-01-30 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. A drug delivery system for increased endosomal escape
WO2025036297A1 (zh) * 2023-08-11 2025-02-20 浙江海昶生物医药技术有限公司 一种具有靶向性的脂质组合物及其制备方法
US20250082776A1 (en) * 2023-08-31 2025-03-13 Massachusetts Institute Of Technology Polyanion coated lipid nanoparticles and methods of use thereof
PL248770B1 (pl) * 2023-11-23 2026-01-26 Politechnika Wroclawska Bilosomy o dodatnim ładunku i sposób ich wytwarzania
WO2025151073A1 (en) * 2024-01-10 2025-07-17 Agency For Science, Technology And Research Composition and nanoparticle suitable for use in the delivery of a therapeutic agent

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010149785A1 (en) 2009-06-26 2010-12-29 Universiteit Gent Cationic liposomes for the delivery of high molecular weight compounds
WO2011075656A1 (en) 2009-12-18 2011-06-23 The University Of British Columbia Methods and compositions for delivery of nucleic acids
JP2014511381A (ja) 2011-02-22 2014-05-15 レオ ファーマ アクティーゼルスカブ ケラチノサイトへの結合のための環状ペプチドおよびその結合体
JP2017533280A (ja) 2014-10-31 2017-11-09 ユニバーシティー オブ ユタ リサーチ ファウンデーションUniversity of Utah Research Foundation 胆汁酸粒子の組成物及び方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100817024B1 (ko) * 2006-11-09 2008-03-26 재단법인 목암생명공학연구소 핵산 또는 약물을 간에 특이적으로 전달하는 복합체 및이를 포함하는 약학적 조성물
US11219634B2 (en) * 2015-01-21 2022-01-11 Genevant Sciences Gmbh Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells
BR112019008481A2 (pt) * 2016-10-26 2020-03-03 Curevac Ag Vacinas de mrna de nanopartículas lipídicas
EP3558356A2 (en) * 2016-12-23 2019-10-30 CureVac AG Mers coronavirus vaccine
WO2019046809A1 (en) * 2017-08-31 2019-03-07 Modernatx, Inc. METHODS OF MANUFACTURING LIPID NANOPARTICLES

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010149785A1 (en) 2009-06-26 2010-12-29 Universiteit Gent Cationic liposomes for the delivery of high molecular weight compounds
WO2011075656A1 (en) 2009-12-18 2011-06-23 The University Of British Columbia Methods and compositions for delivery of nucleic acids
JP2014511381A (ja) 2011-02-22 2014-05-15 レオ ファーマ アクティーゼルスカブ ケラチノサイトへの結合のための環状ペプチドおよびその結合体
JP2017533280A (ja) 2014-10-31 2017-11-09 ユニバーシティー オブ ユタ リサーチ ファウンデーションUniversity of Utah Research Foundation 胆汁酸粒子の組成物及び方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Manish Singh et al.,Unraveling the impact of hydroxylation on interactions of bile acid cationic lipids with model membranes by in-depth calorimetry studies,Phys.Chem.Chem.Phys.,2014年,16,19266-19274,DOI: 10.1039/c4cp02283a
Yoshiyuki Hattori et al.,Transdermal Delivery of Small Interfering RNA with Elastic Cationic Liposomes in Mice,Journal of Pharmaceutics,2013年,Article ID:149695,1-6,DOI: 10.1155/2013/149695

Also Published As

Publication number Publication date
CA3142949A1 (en) 2020-12-17
CN114286671A (zh) 2022-04-05
JP2022538797A (ja) 2022-09-06
EP3982932A4 (en) 2023-10-25
IL288755A (en) 2022-02-01
AU2020290516A2 (en) 2022-03-31
EP3982932A1 (en) 2022-04-20
AU2020290516A1 (en) 2022-01-20
US20220296516A1 (en) 2022-09-22
WO2020252375A1 (en) 2020-12-17
AU2020290516B2 (en) 2026-01-29

Similar Documents

Publication Publication Date Title
JP7772597B2 (ja) 生物学的送達ビヒクルのための組成物及び方法
US20230023615A1 (en) Compositions and methods for biological delivery vehicles
Degors et al. Carriers break barriers in drug delivery: endocytosis and endosomal escape of gene delivery vectors
WO2022260678A1 (en) Compositions and methods for biological delivery vehicles
US20240058454A1 (en) Biological delivery systems
AU2012255194B2 (en) Charge triggering of self-organized nanoparticles
US20190351071A1 (en) Structures and methods for gene therapy
JPWO2008120815A1 (ja) がん細胞および癌随伴線維芽細胞への標的化剤
US20240197636A1 (en) Tissue-specific nucleic acid delivery by mixed cationic lipid particles
US20250041325A1 (en) Lipid-based compositions and methods thereof
US20210177982A1 (en) Mucus-penetrating peptides, delivery vehicles and methods of therapy
US9976142B2 (en) Targeting molecule and a use thereof
KR20140069269A (ko) 상보성 올리고뉴클레오티드 링커를 사용한 표적화된 나노입자들의 원격 조립
US20240269318A1 (en) Nano-delivery systems comprising modified lipids and use thereof
US20150017098A1 (en) Carrier that targets fucosylated molecule-producing cells
JP5615509B2 (ja) フコシル化糖鎖産生細胞用物質送達担体
JP5871247B2 (ja) フコシル化糖鎖産生細胞用物質送達担体
CN117241780A (zh) 生物递送系统
JP5936002B2 (ja) 組合わせ医薬製剤
Park Enhancing Cytosolic Delivery and Gene Regulation Activity of Spherical Nucleic Acids

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230612

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230612

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240806

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250603

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251007

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251106

R150 Certificate of patent or registration of utility model

Ref document number: 7772597

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150